60 Degrees Pharmaceuticals prospectus supplement (Form 424B5) outlines the securities being offered and includes extensive discussion of Tafenoquine (Arakoda) clinical and market opportunities across human and veterinary tick-borne and antifungal indications. The document highlights company-commissioned market research (300 prescribers, 6,000 consumers, claims data) and presents incidence and prevalence estimates: up to 38,000 potentially treatable acute babesiosis cases annually, an estimated minimum ~7,900 persistent babesiosis insurance-claim cases per year, and a modeled tafenoquine-treated market as high as 380,000 annual chronic persistent cases (≈$245 million annual sales; cumulative 1.71 million patients and $1.1 billion sales through patent expiry in 2035). It cites prior cooperative R&D with the U.S. Army and references patents, outstanding warrants (7,587,594 shares at $5.82 average exercise), options (28,437 shares at $23.64 average exercise) and reserved shares (57,068) under the 2022 Plan. The supplement also describes debt securities, unit and trustee provisions, global security/book-entry mechanics and disclosure obligations incorporated by reference to SEC filings.
60 Degrees Pharmaceuticals, Inc. reported an item on an 8-K disclosing a Sales Agreement dated September 5, 2025 between the company and H.C. Wainwright & Co., LLC related to its securities. The filing lists the Sales Agreement as Exhibit 1.1 and includes a legal opinion and consent from Sichenzia Ross Ference Carmel LLP as Exhibits 5.1 and 23.1. The document is signed by Geoffrey Dow, Chief Executive Officer and President.
The filing supplies exhibit-level detail but does not disclose the economic terms, offering size, pricing mechanics, or expected timing for any sales under the agreement. No financial tables, revenue, or earnings data are provided.
60 Degrees Pharmaceuticals, Inc. is soliciting proxies for its upcoming annual meeting to elect five directors and seek shareholder approval on several proposals. The Board recommends voting FOR the election of the five nominees, an amendment to the 2022 Equity Plan to add 250,000 shares, an amendment to the Certificate of Incorporation to permit a reverse stock split at a ratio between 1:3 and 1:10 (to be chosen by the Board), the ratification of RBSM LLP as independent auditor for fiscal 2025, and a proposal to adjourn if additional votes are needed.
The reverse split, if approved, will combine outstanding shares automatically, eliminate fractional shares (entitling holders to whole shares instead), proportionately adjust outstanding options and warrants, and leave authorized shares at 150,000,000. The Board has not recommended votes on other potential matters; proxies may vote discretionarily on such items.
Insider option grant and ownership change at 60 Degrees Pharmaceuticals — Kristen Landon, the company’s Chief Operating Officer, was granted 4,167 stock options with an exercise price of $6.85. The options vest in five equal annual tranches beginning December 31, 2024, and have a 10-year maximum term. After the grant, Landon beneficially owns 4,167 underlying shares directly. The filing notes it was submitted late due to an administrative error and that all figures were retroactively adjusted for a 1-for-5 reverse stock split effected by the issuer.
Kristen Landon, Chief Operating Officer and director of 60 Degrees Pharmaceuticals, Inc., reports acquiring 4,540 shares of the issuer's common stock on 01/17/2025. The reported acquisition was at no cash price ($0) and leaves Ms. Landon with 4,540 shares held directly. The filing notes it was submitted late due to an inadvertent administrative error and that the reported share totals were adjusted to reflect a 1-for-5 reverse stock split effective 02/24/2025. The Form 4 is signed by the reporting person on 08/14/2025. All information is limited to this single non-derivative purchase; no derivative transactions or prices other than $0 are reported.
60 Degrees Pharmaceuticals (SXTP/SXTPW) filing an initial Form 3 showed the reporting person, Kristen Landon, Chief Operating Officer, reports no beneficial ownership of the issuer's securities. The event date triggering the report is 02/12/2024. The filing notes it was submitted late due to an inadvertent administrative error. The form is signed by Ms. Landon on 08/14/2025, and there are no listed non-derivative or derivative holdings on the schedules.
60 Degrees Pharmaceuticals is a specialty pharmaceutical company marketing the FDA-approved malaria prevention product Arakoda and developing additional tafenoquine-based and other programs. For the three months ended June 30, 2025 the company reported net revenue of $257,820 (including $100,932 product revenue and $206,939 research revenue) and a gross profit of $50,881. Cash and cash equivalents were $1,966,930 at June 30, 2025, up from $1,659,353 at December 31, 2024, aided by net financing proceeds of approximately $1.7 million from January and February 2025 registered offerings.
Despite the revenue increase, the company reported a six-month net loss of $3,612,231, used $3,047,494 in operating activities during the six months, and had an accumulated deficit of $44,138,232. Derivative liabilities tied to a contingent milestone (Knight) were $776,172. Management states there is substantial doubt about the company’s ability to continue as a going concern without raising additional capital. The company also faces customer concentration (significant customers comprised ~99% of product revenue for the quarter) and sole-vendor API supply risk.